Literature DB >> 27993327

Percutaneous Treatment of Lymphatic Malformations.

Michael Acord1, Abhay S Srinivasan2, Anne Marie Cahill2.   

Abstract

Lymphatic malformations are slow-flow vascular anomalies composed of dilated lymphatic channels and cysts of varying sizes. Percutaneous treatments, particularly sclerotherapy, play an important role in the treatment of these lesions, often obviating the need for surgical intervention. Owing to the complex nature of these lesions, a multidisciplinary approach should be used to guide diagnosis and management. This submission focuses on the workup and treatment of pediatric lymphatic malformations at our institution, with a focus on sclerotherapy. Therapeutic outcomes and the management of postprocedural complications are also discussed.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lymphatic malformations; Pediatric; Sclerotherapy

Mesh:

Substances:

Year:  2016        PMID: 27993327     DOI: 10.1053/j.tvir.2016.10.001

Source DB:  PubMed          Journal:  Tech Vasc Interv Radiol        ISSN: 1557-9808


  11 in total

1.  Single center experience with intralesional bleomycin sclerotherapy for lymphatic malformations.

Authors:  Hakan Yılmaz; Özlem Yılmaz; İlkay Çamlıdağ; Ümit Belet; Hüseyin Akan
Journal:  Jpn J Radiol       Date:  2017-08-04       Impact factor: 2.374

Review 2.  Contrast-enhanced ultrasound in pediatric interventional radiology.

Authors:  Michael R Acord; Anne Marie Cahill; Rachelle Durand; Dean Y Huang; Sphoorti Shellikeri; Seth Vatsky; Abhay Srinivasan
Journal:  Pediatr Radiol       Date:  2021-05-12

3.  The Addition of Lipid-Based Contrast Medium does not Inactivate the Detergent Sclerosant Sodium Tetradecyl Sulfate in-vitro.

Authors:  Charlotte L Oliver; Judy Brown; Mike Watkins; Ian McCafferty; Richard J Oliver
Journal:  Cardiovasc Intervent Radiol       Date:  2021-03-11       Impact factor: 2.740

4.  Doxycycline sclerotherapy for post-traumatic inguinal lymphocele in a child.

Authors:  Amanda W Harrington; John J Tackett; Brendon L Graeber; Robert A Cowles
Journal:  BMJ Case Rep       Date:  2018-01-23

Review 5.  Nodal and Pedal MR Lymphangiography of the Central Lymphatic System: Techniques and Applications.

Authors:  Claus Christian Pieper
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

Review 6.  Vascular anomalies: clinical perspectives.

Authors:  Joao Guilherme Amaral; Irene Lara-Corrales
Journal:  Pediatr Radiol       Date:  2022-01-05

Review 7.  The Role of Interventional Radiologists in the Treatment of Congenital Lymphatic Malformations.

Authors:  Julie Cronan; Anne E Gill; Jay H Shah; C Matthew Hawkins
Journal:  Semin Intervent Radiol       Date:  2020-07-31       Impact factor: 1.513

8.  Topical sirolimus 0.1% for treating cutaneous microcystic lymphatic malformations in children and adults (TOPICAL): protocol for a multicenter phase 2, within-person, randomized, double-blind, vehicle-controlled clinical trial.

Authors:  Sophie Leducq; Agnès Caille; Sébastien Barbarot; Nathalie Bénéton; Didier Bessis; Olivia Boccara; Anne-Claire Bursztejn; Christine Chiaverini; Anne Dompmartin; Catherine Droitcourt; Valérie Gissot; Dominique Goga; Laurent Guibaud; Denis Herbreteau; Anne Le Touze; Christine Léauté-Labrèze; Gérard Lorette; Stéphanie Mallet; Ludovic Martin; Juliette Mazereeuw-Hautier; Alice Phan; Patrice Plantin; Isabelle Quéré; Pierre Vabres; Hélène Bourgoin; Bruno Giraudeau; Annabel Maruani
Journal:  Trials       Date:  2019-12-17       Impact factor: 2.279

9.  Liposuction-Like Sclerotherapy Technique for Microcystic Lymphatic Malformation.

Authors:  Huaijie Wang; Chong Xie; Weilong Lin; Jinbang Zhou; Weijia Yang; Zhengtuan Guo
Journal:  Cureus       Date:  2022-03-03

10.  Lymphatic malformations in children: treatment outcomes of sclerotherapy in a large cohort.

Authors:  Frédérique C M Bouwman; Silje S Kooijman; Bas H Verhoeven; Leo J Schultze Kool; Carine J M van der Vleuten; Sanne M B I Botden; Ivo de Blaauw
Journal:  Eur J Pediatr       Date:  2020-10-13       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.